MedTrace Logo

QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study

NCT05305534 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2142

Last updated 2025-09-24

No results posted yet for this study

Summary

Study for performance evaluation of the QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel in comparison with other chosen comparator methods

Conditions

  • Blood Disease

Interventions

DEVICE

QIAstat-Dx® BCID GN and GPF Plus AMR Panels

The performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested

Sponsors & Collaborators

  • QIAGEN Gaithersburg, Inc

    lead INDUSTRY

Principal Investigators

  • Sarah Johnson · QIAGEN Gaithersburg, Inc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-04-10
Completion
2025-08-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305534 on ClinicalTrials.gov